Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Neoplants

Explore full profile

The first generation of bioengineered plants to fight air pollution

Paris, FranceFounded 2018Biotechnology
Valuation $100–250M Last recorded · 2022
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Neoplants and the history behind them.

About Neoplants

Neoplants, a Parisian biotech company established in 2018, is focused on developing bioengineered plants to combat indoor air pollution. The company was founded by Lionel Mora, who serves as CEO, and Patrick Torbey, the CTO. Mora brings a business and product marketing background from his time at Google, while Torbey contributes his expertise in genetics, holding a PhD in genome editing from Ecole Normale Supérieure in Paris. Their collaboration began at the Station F startup incubator, driven by a shared vision to apply bioengineering to solve real-world environmental problems.

The company's core business revolves around creating "plants with a purpose" by enhancing their natural ability to purify the air. Neoplants targets the significant issue of indoor air pollution, which can be up to five times higher than outdoor levels, by focusing on volatile organic compounds (VOCs). Its primary product, initially named Neo P1 and later referred to as Neo Px, is a bioengineered Pothos (Epipremnum aureum) plant. This system is engineered to be up to 30 times more effective than standard houseplants at capturing and metabolizing harmful VOCs like formaldehyde, benzene, toluene, and xylene. Instead of merely storing pollutants, the plant converts them into substances like sugars and amino acids. The system includes the plant, a specially designed pot to maximize airflow, and monthly microbiome supplements called "Power Drops" to maintain peak performance. The business model is direct-to-consumer, initially targeting the U.S. market with a price point around $179 for the complete system.

Neoplants has secured approximately $20 million in funding from investors including True Ventures, Heartcore Capital, Collab Fund, and Entrepreneur First. The company's long-term ambitions extend beyond indoor air purification to larger-scale applications such as carbon capture. While their first fully genetically modified plant, Neo P1, is still navigating regulatory approvals and development, the company has launched Neo Px, which utilizes an enhanced microbiome with a regular Pothos plant to achieve its air-purifying effects. This positions Neoplants in a unique category between ornamental houseplants and mechanical air purifiers, offering a sustainable, nature-based solution.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2018
Headquarters
Paris, France
Employees
31
Open positions
None listed
Dealroom signal
56.8/100
Sector
Biotechnology, Synthetic Biology, Sustainable Development Goals, Urban Tech, Air Quality Monitoring and Treatment, Biodiversity, Climate Tech, NBS, Energy and Greentech, Observatoire Deeptech, Hard Tech, Greentech
Business model
Manufacturing
Client focus
b2b

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VC✓Equity / VC Oct 2022 $20M $80M Niklas Zennström · Entrepreneurs First · Collaborative Fund · Heartcore Capital ↗
SUPPORT PROGRAM✓Other financing Sep 2020 $0 — CDL-Paris —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Neoplants website traffic

Latest recorded traffic for Neoplants is 8.4K monthly website visits, up 58.5% over the last three months. Neoplants's team grew 3.3% over the past year.

Latest monthly visits8.4K 3-month web change+58.5% 1-year team growth+3.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

13 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

Other known investors8 additional known investors

  • CDL-Paris
  • Agoranov
  • Builders VC
  • Dan Widmaier
  • Lucas Liabeuf
  • Partech
  • Stef van Grieken
  • Yacine Ghalim
Team profiled 10 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
4 countries with
team presence
🇫🇷 France70.4%
🇺🇸 United States18.5%
🇬🇧 United Kingdom7.4%
🇲🇽 Mexico3.7%
4 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Neoplants on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Neoplants’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.